Probiotics in women’s health
The human probiotics market size is anticipated to surpass USD 5 billion by 2024 owing to its increasing demand. Probiotics are used to treat Urinary tract infections, diabetes, diarrhea, vulvovaginal candidiasis, and bacterial vaginosis in women. Several in vitro and in vivo studies support the beneficial effect of some strains of lactobacilli on the restoration of the vaginal flora and the prevention of recurrent UTIs.
Related Conference of Probiotics in women’s health
January 18-19, 2027
22nd International Conference on Virology, Emerging Diseases & vaccines
London, UK
February 15-16, 2027
9th International Conference on Clinical Microbiology, Virology and Infectious Diseases
Tokyo, Japan
April 01-02, 2027
22nd International Conference on Microbial Interactions & Microbial Ecology
Madrid, Spain
August 25-26, 2027
13th International Congress on Trauma, Critical Care and Emergency Medicine
Paris, France
Probiotics in women’s health Conference Speakers
Recommended Sessions
- Microbiome
- Pediatric and Infant Health
- Pre and Probiotics futures
- Prebiotics and Diet
- Prebiotics old and new
- Probiotics in Aquaculture
- Probiotics in food security
- Synbiotic
- Food and Fermentation
- Formulations and Production
- Gut Bacteria on COVID Severity
- Gut microbiota
- Microbiota from womb to adult
- Microbiota Protection and Resilience
- New Methods and New Equipment
- Nutrition and Probiotics
- Preterm and term Newborns Probiotics
- Probiotics and COVID-19
- Probiotics in oral health and dentistry
- Probiotics in women’s health
Related Journals
Are you interested in
- Agricultural Microbiology & Plant–Microbe Interactions - Beneficial Microbes 2027 (UK)
- Biofilms & Microbial Surface Interactions - Beneficial Microbes 2027 (UK)
- Critical Care Medicine - TRAUMA 2027 (France)
- Emergency Nursing and Trauma Care - TRAUMA 2027 (France)
- Ethics, Legal, and Policy Issues in Critical Care - TRAUMA 2027 (France)
- Extremophiles & Microbial Adaptation - Beneficial Microbes 2027 (UK)
- Global Health and Trauma Care - TRAUMA 2027 (France)
- Marine Microbiology & Microbial Resources - Beneficial Microbes 2027 (UK)
- Microbial Biomanufacturing & Bioeconomy - Beneficial Microbes 2027 (UK)
- Microbial Biomaterials & Bio-Based Products - Beneficial Microbes 2027 (UK)
- Microbial Communication & Quorum Sensing - Beneficial Microbes 2027 (UK)
- Microbial Diagnostics & Advanced Detection Technologies - Beneficial Microbes 2027 (UK)
- Microbial Ecology & Community Interactions - Beneficial Microbes 2027 (UK)
- Microbial Enzymes & Biocatalysis - Beneficial Microbes 2027 (UK)
- Microbial Evolution & Adaptive Biology - Beneficial Microbes 2027 (UK)
- Microbial Fermentation & Bioprocess Development - Beneficial Microbes 2027 (UK)
- Microbial Metabolites & Bioactive Compounds - Beneficial Microbes 2027 (UK)
- Microbial Resources & Culture Collections - Beneficial Microbes 2027 (UK)
- One Health & Microbial Interactions - Beneficial Microbes 2027 (UK)
- Pediatric and Neonatal Emergency Care - TRAUMA 2027 (France)
- Resuscitation and Emergency Response - TRAUMA 2027 (France)
- Trauma and Emergency Medicine - TRAUMA 2027 (France)
- Trauma Imaging and Diagnostics - TRAUMA 2027 (France)
- Trauma Rehabilitation and Recovery - TRAUMA 2027 (France)
